Publicacións en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Epidemiología Y Salud Pública (4)

2024

  1. Basic host response parameters to classify mortality risk in COVID-19 and community-acquired pneumonia

    Scientific reports, Vol. 14, Núm. 1, pp. 12726

2020

  1. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1043-1057

  2. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1023-1042

  3. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1058-1068